Water

Water

SCHEMBL7042934

CCCC(O)CC(C)=O.O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 1/20 0.39
CHRM3 known ✓ P20309 1/20 0.39
HTR2A known ✓ P28223 1/20 0.39
HTR2C known ✓ P28335 1/20 0.39
ADRA1A known ✓ P35348 1/20 0.39
HRH1 known ✓ P35367 1/20 0.39
DRD3 known ✓ P35462 1/20 0.39
SLC6A3 known ✓ Q01959 1/20 0.39
HDAC1 known ✓ Q13547 1/20 0.39
HDAC2 known ✓ Q92769 1/20 0.39
HDAC7 known ✓ Q8WUI4 1/20 0.34
HDAC8 known ✓ Q9BY41 1/20 0.34
HDAC6 known ✓ Q9UBN7 1/20 0.34
HDAC9 known ✓ Q9UKV0 1/20 0.34
HDAC5 known ✓ Q9UQL6 1/20 0.34
FDPS known ✓ P14324 1/20 0.32
GPR84 Q9NQS5 7/20 0.43
TDP1 Q9NUW8 3/20 0.42
ALDH1A1 P00352 2/20 0.42
AKR1A1 P14550 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441054 0.97
SCHEMBL62312 0.97
SCHEMBL20530452 0.97
SCHEMBL14492106 0.86 ALDH1A1 (0.39) GPR84TDP1ALDH1A1CHRM1AKR1A1
SCHEMBL14286229 0.83 GPR84 (0.57) GPR84TDP1ALDH1A1NFKB1FFAR1
SCHEMBL20530457 0.83 GPR84 (0.57) GPR84TDP1ALDH1A1NFKB1FFAR1
SCHEMBL261661 0.81 GPR84 (0.67) GPR84NFKB1FFAR1FFAR4
SCHEMBL14802263 0.81 GPR84 (0.67) GPR84NFKB1FFAR1FFAR4
SCHEMBL4567252 0.81 GPR84 (0.67) GPR84NFKB1FFAR1FFAR4
Water SCHEMBL1672220 0.80 GPR84 (0.65) GPR84TDP1CHRM1AKR1A1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229028-A1 Methods and compositions for reducing side effects in chemotherapeutic treatments GALECTIN THERAPEUTICS, INC. 2003-12-11 US disclosed
US-6642205-B2 Administering conjugate such as N-(beta-D-galactopyranosyl -(1-4)-beta-O-D-sorbityl)doxorubicin, wherein chemotherapeutic treatment includes adriamycin PRO-PHARMACEUTICALS, INC. 2003-11-04 US disclosed
US-20020068077-A1 Methods and compositions for reducing side effects in chemotherapeutic treatments GALECTIN THERAPEUTICS, INC. 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068077-A1 Methods and compositions for reducing side effects in chemotherapeutic treatments PAICS, B3GAT3, GALE CHRM1 3798/4885CHRM3 2931/4885HTR2A 3992/4885
US-20030229028-A1 Methods and compositions for reducing side effects in chemotherapeutic treatments PAICS, B3GAT3, GALE CHRM1 3798/4885CHRM3 2931/4885HTR2A 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.